



ResistancePlus® MG FleXible

M. genitalium + macrolide resistance

Resistance Plus® MG Flexible offers simultaneous detection and identification of Mycoplasma genitalium and azithromycin (macrolide) resistance in ~ 2 hours to support appropriate treatment decisions at the earliest opportunity for improved patient management.





ResistancePlus® MG FleXible

ResistancePlus® MG FleXible brings **accuracy and simplicity** to your lab in combination with GeneXpert® Systems* for a complete solution. Detect both M. genitalium and macrolide resistance markers in a single test and help overcome the challenges of treating M. genitalium due to high levels of azithromycin resistance.⁴



The Challenges:

- ▶ M. genitalium is a recognised Sexually Transmitted Infection (STI), treated syndromically, with clinical presentation similar to that of *Chlamydia trachomatis*.¹
- ▶ Prevalence of M. genitalium infections in the general population ranges from 1-3%, with an increased incidence in men with non-gonococcal urethritis (NGU) (10-20%).²
- ▶ M. genitalium infections contribute to 10–35% of non-chlamydial non-gonococcal urethritis in men and in women, it is also associated with cervicitis and pelvic inflammatory disease (PID).³
- ▶ M. genitalium treatment is challenging due to high levels of macrolide resistance.⁴

The Need:

- ▶ Macrolide resistance testing is recommended by international and local guidelines on management of M. genitalium infections.^{2,3,5-7}
- ► Macrolide resistance testing can guide appropriate treatment choice enabling Resistance Guided Therapy.⁵
- Resistance Guided Therapy is clinically demonstrated to improve patient cure rate and overall patient management.8
- ▶ Fast detection of macrolide resistance can reduce time to cure, preventing ongoing transmission.8

The Solution:

- ▶ ResistancePlus® MG FleXible detects both M. genitalium and macrolide resistance in ~ 2 hours.
- ResistancePlus® MG FleXible offers a fast and simple solution in combination with GeneXpert® Systems. Easily implemented into your existing workflow or setting, with minimal preparation time ~ 10 mins.
- ▶ High performance test validated on **wide range of specimen types** and collection devices, including urine and swabs (vaginal, cervical, rectal).**


^{*} CE-IVD. In Vitro Diagnostic Medical Device.

^{**}Validated specimens: male and female urine, vaginal swab, cervical swab, rectal swab, urethral swab, from symptomatic and asymptomatic patients. Validated collection kits: Xpert® Vaginal/Endocervical and Xpert® Urine Specimen Collection Kits, Neat urine, Regular FLOQSwab™ in 3 ml of UTM™ media, cobas PCR collection media. For details refer to the *ResistancePlus*® MG FleXible Instructions For Use (IF-IV0012)

Impact on Patient Pathway

Improving patient management

ResistancePlus® MG FleXible provides therapeutic guidance recommendations, enabling clinicians to make informed treatment decisions. Resistance guided therapy is clinically demonstrated to increase overall patient cure rate.8



ResistancePlus® MG FleXible

Validated on a wide range of sample types including **rectal**, male and female **urine**, and common collection **swab** kits including Xpert® CT/NG Vaginal/Endocervical Specimen Collection kit and Xpert® CT/NG Urine Specimen Collection Kit.**

Clinical Performance[†]



	MG Detection	Markers
Sensitivity	100%	92.9%
Specificity	96.3%	100%

Resistance



Expected MG negative	Expected MG positive, wild type	Expected MG positive, mutant
33/33	1/1	3/4
22/22	6/6	10/10

[†] All performance results at 95% confidence interval. For details refer to the **Resistance**Plus® MG FleXible Instructions For Use (IF-IV0012)

Simple Implementation into Existing Workflow

Easy preparation — Hands-on time < 10 min

1. Prepare reaction mix





2. Transfer samples and Internal Control





3. Insert Cartridge and start test, results in ~2 hours



Product	Size	Cat#
ResistancePlus® MG FleXible	10 tests	S2A-2000410
ResistancePlus® MG S2A Positive Control	10 tests	S2A-95004

ResistancePlus® MG FleXible Improve patient management. Test for macrolide resistance.

In Vitro Diagnostic Medical Device
Not available in all countries

References:

- 1. Manhart LE and Kay N. Mycoplasma genitalium: Is It a Sexually Transmitted Pathogen? Curr. Infect. Dis. Reps. 2010; 12(4):306-313.
- 2. 2018 BASHH UK national guideline for the management of infection with Mycoplasma genitalium. Available online at https://www.bashhguidelines.org/media/1198/mg-2018.pdf
- 3. Jensen et al. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1650-1656.
- 4. Unemo, M et al. Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium. Nat Rev Urol. 2017 Mar;14(3):139-152.

 5. Homer PJ et al. 2016 European guideline on the management of non-gonococcal urethritis. Int J STD AIDS. 2016 Oct;27(11):928-37.
- 6. Australian STI Management Guidelines Mycoplasma genitalium 2018. http://www.sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium
- 7. Groupe Infectiologie Dermatologique et Infections Sexuellement GRIDIST and Société Fançaise de Dermatologie Press Release. Available online at: https://www.sfdermato.org/actualites/communique-commun-gridist-et-sfd.html
- 8. Read TRH et al. Outcomes of Resistance-guided Sequential Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation. Clin Infect Dis. 2019 Feb 1;68(4):554-560.

ResistancePlus® MG FleXible tests are developed and manufactured by SpeeDx Pty Ltd, Sydney. PlexPCR® & ResistancePlus® are trademarks of SpeeDx Pty Ltd. Other copyright and trademarks are the property of the respective owners. SpeeDx Pty Ltd products may be covered by one or more local or foreign patents. Visit www.plexpcr.com/patents for comprehensive patent information.



Europe - SpeeDx Ltd. +44 (0)333 577 5210 sales.uk@speedx.com.au

Acre House 11/15 William Road London NW1 3ER United Kingdom



Exclusively distributed by Cepheid under the FleXible $_{\text{for GeneXpert}^{\circ}\text{System}}$ program.

Cepheid European Headquarters +33-563-82-53-00 cepheid@cepheideurope.fr

Vira Solelh 81470 Maurens-Scopont France